CEO Weekly Q&A

Oren Gilad, Ph.D., President & CEO, Aprea Therapeutics

Oren Gilad, Ph.D., is President and CEO of Aprea Therapeutics (Nasdaq: APRE), a Doylestown, Pennsylvania-based clinical-stage precision oncology company built around the principle of synthetic lethality — exploiting the specific vulnerabilities that cancer-driving mutations create. Dr. Gilad's path to Aprea began in the lab: research he conducted at the University of Pennsylvania on the DNA damage response in RAS-driven cancers convinced him of the power of targeting these dependencies selectively, an insight that led him to found Atrin Pharmaceuticals and later take the helm at Aprea. The company's lead program, APR-1051, is a WEE1 inhibitor now in a first-in-human Phase 1 trial for patients with biomarker-defined solid tumors.

‍

In this Q&A, Dr. Gilad discusses what differentiates APR-1051 from earlier WEE1 inhibitors, the biomarker strategy behind Aprea's approach to precision oncology, and the milestones the company is working toward next. He also reflects on the realities of leading a clinical-stage biotech through scientific and financial uncertainty, the culture he's building at Aprea, and why the Greater Philadelphia life sciences ecosystem has been an asset to the company's growth.

Your Story

Q1. What was the defining moment or insight that led you to start — or take the helm of — your company?

One of the defining moments for me came from work I did at the University of Pennsylvania studying the relationship between oncogenic RAS and the DNA damage response. We reduced ATR expression in RAS-transformed cancer cells and saw a dramatic effect on their survival. What was particularly striking was the selectivity: the same degree of ATR reduction had a much smaller effect on normal cells.

‍

That experiment stayed with me because it demonstrated, very clearly, the power of synthetic lethality. If you can identify and precisely target those dependencies, you have the potential to kill cancer cells while preserving normal tissue.

‍

That insight shaped much of my career and ultimately led me to start Atrin Pharmaceuticals, and now to lead Aprea. I saw an opportunity to build a company around precision oncology and synthetic lethality by developing drugs that exploit the specific vulnerabilities created by cancer-driving alterations.

‍

For me, it was a direct line from an experiment at Penn, where I first saw how profound that therapeutic window could be, to the strategy we're pursuing today.

‍

Q2. In the simplest terms, what does Aprea do, and why does it matter for patients?

At Aprea, we're working to treat cancer through synthetic lethality — targeting the DNA damage response pathway that many tumors depend on to survive. Our goal is to connect the right drug with the right biological vulnerability in the right patient. Rather than a one-size-fits-all approach, we match specific tumors with therapeutic candidates designed to exploit their unique biology and kill the cancer cell.

‍

‍

The Science & The Strategy

Q3. What is it about your approach — your platform, your technology, your pipeline — that sets you apart from others working in this space?

WEE1 has been a compelling therapeutic target for many years, but it's been notoriously difficult to drug because of the narrow therapeutic index of many WEE1 inhibitors. Our solution is APR-1051, a WEE1 inhibitor designed specifically to address these limitations by enhancing selectivity for WEE1 and limiting off-target effects. Another key part of our strategy is matching the drug to patients whose tumors carry specific biomarkers indicating they're more likely to respond to treatment. By combining enhanced specificity with biomarker-defined tumor targeting, we're embracing the precision in precision medicine in every sense of the word.

‍

Q4. What has been your most important milestone to date, and what's the next one you're working toward?

Our most important milestone to date was driving APR-1051 into the clinic and initiating our first-in-human Phase 1 trial. It is the culmination of years of hard work by our team. The next big milestone will be the data readout from that ongoing study, which will include safety, tolerability, and preliminary efficacy data to guide how we advance the program.

‍

Q5. What is the biggest scientific or business challenge you're facing right now, and how are you tackling it?

The biggest challenge in oncology isn't simply finding a drug that can kill cancer cells — it's identifying the patients whose tumors are truly dependent on the pathway you're targeting, and then clearly demonstrating that biology in the clinic.

This is particularly important with synthetic lethality. The science can be compelling, but the value ultimately comes from matching the right drug to the right molecular vulnerability. At Aprea, we're integrating clinical data, tumor genomics, pharmacology, and translational biology in real time. As we learn from every patient, we refine which biomarkers are most predictive of response and use those insights to guide development.

‍

Leadership & Ecosystem

Q6. What has surprised you most about being a CEO in life sciences — something you didn't fully appreciate until you were in the role?

What's surprised me most is how much of the CEO role is about leading under pressure and uncertainty. You have to follow the data, but you rarely have the luxury of having all of it before making an important decision. You're constantly making calls while the information is still evolving.

‍

Q7. How would you describe the culture you're building at Aprea, and why does that matter for the science?

At Aprea, we're building a culture that's scientifically rigorous, highly collaborative, and grounded in humility. In a small biotech, every person needs a clear sense of purpose — it's a major factor in driving our work to develop better therapies for patients.

‍

Q8. What role does the Greater Philadelphia life sciences ecosystem play in Aprea's growth?

Being in the Greater Philadelphia region is a real asset for a company at our stage. The area has an extremely deep bench of pharmaceutical and biotech talent, which has allowed us to build an exceptional team. Aprea is based at the Pennsylvania Biotechnology Center in Bucks County, one of the country's leading nonprofit life sciences incubators, alongside some of the most innovative biotech companies in the region. That environment gives us access to infrastructure, shared resources, and a built-in network of peers and expertise, which lets us stay capital-efficient and focused on advancing our programs rather than building overhead. It's a great ecosystem, and we couldn't be prouder to be part of it.

‍

Looking Ahead

Q9. Where do you see Aprea in three years, and what will have to go right to get there?

Three years from now, success for Aprea would mean we've translated our science into meaningful clinical benefit for patients. I'd like to see our WEE1 inhibitor, APR-1051, clinically validated in biomarker-defined patient populations, with a clear development strategy to support registration. I'm also looking toward continued progress on our ATR inhibitor and p53 reactivator programs.

‍

Q10. What is one thing about the life sciences industry today that you would change if you could?

If I could change one thing about our industry today, it would be reducing the cost of clinical trials in the United States.

‍

‍

About The Big4Bio CEO Weekly Q&A

Every Monday, Big4Bio spotlights a life sciences CEO from one of our eight coverage regions — Boston, San Francisco Bay Area, San Diego, Philadelphia, New York City, the Capital Region, Los Angeles, and Seattle. Each feature is promoted across all eight Big4Bio daily newsletters, reaching 30,000+ life sciences professionals. CEO participation is complimentary and editorial — every CEO approves the final Q&A before publication.

‍

Are you a life sciences CEO or do you represent one? Contact Big4Bio editor Marie Daghlian at marie@big4bio.com to be considered for an upcoming feature.

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.